Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1046/j.1540-8167.14.s9.23.x http://scihub22266oqcxt.onion/10.1046/j.1540-8167.14.s9.23.x 12950527!ä!12950527 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=12950527&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\12950527.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       J+Cardiovasc+Electrophysiol 2003 ; 14 (9 Suppl): S87-95 Nephropedia Template TP {{tp|p=12950527|t=2003. Use of nonantiarrhythmic drugs for prevention of sudden cardiac death |pdf=|usr=}}{{12950527}} gab.com Text Use of nonantiarrhythmic drugs for prevention of sudden cardiac death JO: J Cardiovasc Electrophysiol http://www.kidney.de/pget.php?&tw=1&pmid=12950527 #FOAvip It is of interest that the drugs having the most significant impact on total and sudden death mortality are those without direct electrophysiologic actions on myocardial excitable tissue. This observation may provide insight into mechanisms responsible for ventricular tachyarrhythmias causing cardiac arrest. One way to think about ventricular fibrillation is that it is the final common pathway of an electrically unstable heart. After all, the heart can "die" in only three major ways: electromechanical dissociation, asystole and heart block, and ventricular fibrillation, with the latter most common. It is the "upstream" events provoking the electrical instability that these drugs probably act upon (i.e., ischemia, fibrosis). Although we unquestionably need to pursue investigations into the electrophysiology of these ventricular tachyarrhythmias, more studies need to investigate the drugs affecting upstream events, because these agents appear to yield the greatest dividends, at least for the present. This article reviews these drugs and how they may be effective. Twit Text FOAVip Use of nonantiarrhythmic drugs for prevention of sudden cardiac death ????J Cardiovasc Electrophysiol http://www.kidney.de/pget.php?&tw=1&pmid=12950527 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=12950527 #FOAvip English Wikipedia <ref>{{Cite pmid|12950527}}</ref> Use of nonantiarrhythmic drugs for prevention of sudden cardiac death #MMPMID12950527 Alberte C; Zipes DP J Cardiovasc Electrophysiol 2003[Sep]; 14 (9 Suppl): S87-95 PMID12950527show ga It is of interest that the drugs having the most significant impact on total and sudden death mortality are those without direct electrophysiologic actions on myocardial excitable tissue. This observation may provide insight into mechanisms responsible for ventricular tachyarrhythmias causing cardiac arrest. One way to think about ventricular fibrillation is that it is the final common pathway of an electrically unstable heart. After all, the heart can "die" in only three major ways: electromechanical dissociation, asystole and heart block, and ventricular fibrillation, with the latter most common. It is the "upstream" events provoking the electrical instability that these drugs probably act upon (i.e., ischemia, fibrosis). Although we unquestionably need to pursue investigations into the electrophysiology of these ventricular tachyarrhythmias, more studies need to investigate the drugs affecting upstream events, because these agents appear to yield the greatest dividends, at least for the present. This article reviews these drugs and how they may be effective. |Angiotensin-Converting Enzyme Inhibitors/classification/*therapeutic use[MESH] |Anti-Arrhythmia Agents/*therapeutic use[MESH] |Comorbidity[MESH] |Death, Sudden, Cardiac/*epidemiology/*prevention & control[MESH] |Europe/epidemiology[MESH] |Fatty Acids, Omega-3/therapeutic use[MESH] |Fibrinolytic Agents/therapeutic use[MESH] |Humans[MESH] |Hypolipidemic Agents/classification/*therapeutic use[MESH] |Magnesium/therapeutic use[MESH] |Mineralocorticoid Receptor Antagonists/therapeutic use[MESH] |Randomized Controlled Trials as Topic[MESH] |Spironolactone/*therapeutic use[MESH] |Survival Analysis[MESH] |Treatment Outcome[MESH] |United States/epidemiology[MESH]Use of nonantiarrhythmic drugs for prevention of sudden cardiac death (epmc).pdf DeepDyve Pubget Overpricing